Genzyme meets clinical targets with new trial of mipomersen

Genzyme has reported positive results from a phase III clinical trail of a new homozygous familial hypercholesterolemia treatment.

Findings from the study have been published in medical journal the Lancet and showed that Genzyme’s mipomersen demonstrated a high level of lipid reduction among patients.

This means that the drug was able to meet its primary endpoint in what was one of the largest trials relating to the rare and dangerous disease yet conducted.

Professor Frederick Raal, the study’s primary investigator, stated this represented significant progress in the development of treatments for the illness, with current therapies failing to provide sufficient lipid lowering.

He said: “Mipomersen has the potential to set a new standard of care for this difficult-to-treat disease.”

Earlier this month, the company submitted an application to the Food and Drug Administration for a new cancer drug developed in collaboration with Seattle Genetics, with the latter company receiving a milestone payment as a result.